Grant Bogle, Epizyme CEO
March 1, 2022 10:27 AM ESTUpdated March 4, 08:57 AM
People
R&D

Epizyme joins the queue of biotechs now hand­ing out pink slips, con­serv­ing cash

John Carroll

Editor & Founder

You can add Epizyme to the ros­ter of biotechs re­or­ga­niz­ing and down­siz­ing — in staff and R&D projects — in the face of a bru­tal bear mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Al­ny­lam eyes big­ger dis­eases in more tis­sue types at ‘in­flec­tion point’ for siR­NA

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times